2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer. Academic Article Review uri icon

Overview

MeSH

  • Clinical Trials, Phase III as Topic
  • Humans
  • Neoplasm Staging
  • Randomized Controlled Trials as Topic

MeSH Major

  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms

abstract

  • An American Society of Clinical Oncology (ASCO) focused update updates a single recommendation (or subset of recommendations) in advance of a regularly scheduled guideline update. This document updates one recommendation of the ASCO Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer (NSCLC) regarding switch maintenance chemotherapy. Recent results from phase III clinical trials have demonstrated that in patients with stage IV NSCLC who have received four cycles of first-line chemotherapy and whose disease has not progressed, an immediate switch to alternative, single-agent chemotherapy can extend progression-free survival and, in some cases, overall survival. Because of limitations in the data, delayed treatment with a second-line agent after disease progression is also acceptable. Seven randomized controlled trials of carboxyaminoimidazole, docetaxel, erlotinib, gefitinib, gemcitabine, and pemetrexed have evaluated outcomes in patients who received an immediate, non-cross resistant alternative therapy (switch maintenance) after first-line therapy. In patients with stage IV NSCLC, first-line cytotoxic chemotherapy should be stopped at disease progression or after four cycles in patients whose disease is stable but not responding to treatment. Two-drug cytotoxic combinations should be administered for no more than six cycles. For those with stable disease or response after four cycles, immediate treatment with an alternative, single-agent chemotherapy such as pemetrexed in patients with nonsquamous histology, docetaxel in unselected patients, or erlotinib in unselected patients may be considered. Limitations of this data are such that a break from cytotoxic chemotherapy after a fixed course is also acceptable, with initiation of second-line chemotherapy at disease progression.

publication date

  • October 1, 2011

has subject area

  • Carcinoma, Non-Small-Cell Lung
  • Clinical Trials, Phase III as Topic
  • Humans
  • Lung Neoplasms
  • Neoplasm Staging
  • Randomized Controlled Trials as Topic

Research

keywords

  • Journal Article
  • Practice Guideline

Identity

Language

  • eng

PubMed Central ID

  • PMC3675703

Digital Object Identifier (DOI)

  • 10.1200/JCO.2010.34.2774

PubMed ID

  • 21900105

Additional Document Info

start page

  • 3825

end page

  • 3831

volume

  • 29

number

  • 28